Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Phase 2

Terminated

Conditions: Macular Degeneration
Choroidal Neovascularization

Interventions: Drug: STAKEL

Registration Number: NCT01021956

Lead Sponsor: Steba Biotech S.A.

Brief Summary: The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD). The drug product is activated in patients by exposure to light at a specific wavelength ("Vascular Targeted Photodynamic therapy", "VTP"). The exploratory objective is to assess whether it is possible to delay or reduce the requirement for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12 weeks after VTP.

All subjects will have a 52 weeks safety follow up telephone call (Not for Adverse Events (AEs) collection).

Detailed Description: The primary objective of this Phase IIa clinical study is to evaluate the safety of treatment with Stakel®-mediated VTP in subjects with neovascular AMD. The secondary objective of this Phase IIa clinical study is to explore the effect of treatment with Stakel®-mediated VTP in subjects with neovascular AMD. The exploratory objective is to assess whether it is possible to delay or reduce the requirement for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12 weeks after VTP.

All subjects will have a 52 weeks safety follow up telephone call. (Not for AEs collection).

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 10

Inclusion Criteria

Twenty eight days or more after at least one ranibizumab injection, recurrent leakage on Fluorescein Angiography (FA) from subfoveal Choroidal NeoVessels (CNV) secondary to AMD.
Total lesion size not exceeding 5400 μm in its greatest linear dimension.
Best Corrected Visual Acuity (BCVA) letter score of 73 to 23 in the study eye at a starting distance of 4 meters.
No contraindication to intravitreal ranibizumab injection.
Postmenopausal for at least 12 months prior to enrollment or practicing medically acceptable form of birth control and not pregnant. Male subjects must be practicing a medically acceptable form of birth control.

Exclusion Criteria

Prior treatments:
- Previous subfoveal laser photocoagulation, external-beam radiation therapy, or transpupillary thermoTherapy (TTT) in the study eye at any time.
- Using anti-VEGF therapies for other indications (e.g., cancer) in the 30 days prior to the study and/or during the study
- Received anti-VEGF injection in study eye during less than 28 days prior to Day 1 of the study.
- More than three previous photodynamic therapy (PDT) treatments in the preceding 12 months.
- Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within the preceding month.
- History of vitrectomy,of glaucoma filtering surgery,submacular surgery or other surgical intervention in the study eye.
- History of corneal transplant in the study eye.
- Previous participation in any studies of investigational drugs within 1 month preceding Day 1 (excluding vitamins and minerals).
Lesion Characteristics
- Permanent structural damage to the center of the fovea of the study eye, or a concurrent ocular or systemic condition that could contraindicate administration of an investigational drug, or render the subject at a high risk of treatment complications.
- Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either ≥50% of the total lesion area or ≥1 disc area in size.
- Subfoveal fibrosis or atrophy in the study eye which is at least 50% of the lesion.
- CNV in either eye due to other causes.
- Retinal pigment epithelial tear involving the macula in the study eye.
Concurrent Ocular Conditions
- Active intraocular inflammation (grade trace or above) or current vitreous hemorrhage or rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye.
- History of idiopathic or autoimmune-associated uveitis in either eye.
- Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
- Aphakia or absence of the posterior capsule in the study eye.
- Spherical equivalent of the refractive error in the study eye demonstrating more-than eight diopters of myopia.
- Intraocular surgery (including cataract surgery) in the study eye within three months preceding Day 1.
- Uncontrolled glaucoma in the study eye.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
WST11 (STAKEL)	STAKEL	Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².

Primary Outcome Measures

Name	Time	Method
Adverse Events (AEs) - Number of Subjects With Eye Disorders	12 week follow-up	Adverse events (AEs) consisting in Eye disorders, related or non related were collected throughout the study.

Secondary Outcome Measures

Name	Time	Method
Visual Acuity	Week 12.	Variation from baseline to week 12 in visual acuity score using Early Treatment Diabetic Retinopathy Study (ETDRS) 4.0 meter distance acuity chart. The patient is asked to read letter on a board from a distance of 4 meters. The charts use a geometric progression in letter size from line to line. The scores range from 0 (worse outcome) to 100/100 (best outcome)

Trial Locations

Locations (4): Johns Hopkins,Wilmer Eye Institute
🇺🇸
Baltimore, Maryland, United States
Palmetto Retina Center
🇺🇸
West Columbia, South Carolina, United States
Hotel Dieu de Paris Hospital
🇫🇷
Paris, France
Valley Retina Institute
🇺🇸
Harlingen, Texas, United States